Synthetic Hormones Market Report 2026

Synthetic Hormones Market Overview

• Synthetic Hormones market size has reached to $6.71 billion in 2025 • Expected to grow to $8.34 billion in 2030 at a compound annual growth rate (CAGR) of 4.5% • Growth Driver: The Rise In Hormonal Imbalances Fueling The Growth Of The Market Due To Increasing Demand For Hormone Replacement Therapies • Market Trend: High‑Concentration Growth Hormone Formulation Aims To Improve Access And Treatment Convenience • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Synthetic Hormones Market?

Synthetic hormones are artificially produced substances that mimic the function of natural hormones in the body. These hormones are typically created through chemical synthesis rather than being derived from natural sources and are used in medical treatments to regulate various physiological processes or to replace hormones that the body may not produce in sufficient quantities. The main types of synthetic hormones are steroid hormones, peptide hormone, amino acid derivatives, and others. Steroid hormones are a class of hormones derived from cholesterol and characterized by their structure, which includes four interconnected carbon rings. Various routes of administration involve oral, nasal, topical, and intravenous administration. Various applications include growth hormone deficiency, thyroid hormone deficiency, menopause, male hypogonadism, and others, and are used by various end users such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Synthetic Hormones Market Growth Forecast?

The synthetic hormones market size is expected to see steady growth in the next few years. It will grow to $8.34 billion in 2030 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to integration of ai in hormone therapy, development of oral and non-invasive hormone delivery, growth in personalized medicine, expansion of online pharmacy platforms, innovation in peptide and amino acid derivative hormones. Major trends in the forecast period include personalized hormone therapy development, advanced drug delivery systems, synthetic hormone formulation innovation, growth in hormone replacement therapy adoption, regulatory compliance and quality standards.

What Is The Driver Of The Synthetic Hormones Market?

The rising incidence of hormonal imbalances is expected to propel the growth of the synthetic hormones market going forward. Hormonal imbalances occur when the body produces too much or too little of certain hormones, leading to disruptions caused by aging, stress, lifestyle factors, or underlying medical conditions. These imbalances often require therapeutic intervention, and synthetic hormones play a vital role by supplementing or replacing deficient hormones to restore normal physiological function and alleviate associated symptoms. The growing demand for hormone replacement therapy (HRT) reflects the increasing prevalence of these conditions. For instance, in January 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization,polycystic ovary syndrome is a significant public health concern and one of the most common hormonal disorders among women of reproductive age, affecting an estimated 6–13%, with up to 70% of cases remain undiagnosed. Therefore, the rising incidence of hormonal imbalances is driving the growth of the synthetic hormones industry.

Key Players In The Global Synthetic Hormones Market

Major companies operating in the synthetic hormones market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol Myers Squibb Company, Sanofi SA, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Merck & Co. Inc, Teva Pharmaceutical Industries Ltd., Ferring B.V., Endo Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., IBSA Institute Biochimique SA, American Regent Inc., McGuff Pharmaceuticals Inc., Anhui Anke Biotechnology Co.Ltd, Acerus Pharmaceuticals Corporation, Slayback Pharma LLC

Global Synthetic Hormones Market Trends and Insights

Major companies operating in the synthetic hormone market are focusing on developing innovative biosimilar formulations, such as high‑concentration recombinant human growth hormone (rhGH), to meet the rising demand for more accessible and affordable therapies for growth‑hormone deficiency and short stature. High‑concentration rhGH refers to a form of synthetic growth hormone (typically somatropin) produced via recombinant DNA technology, with an increased drug load per volume, which allows for smaller injection volumes, greater convenience, and potentially better treatment adherence compared to traditional lower‑concentration formulations. For instance, in May 2025, Sandoz AG a Switzerland‑based leader in generics and biosimilars, launched OMNITROPE in a new 15 mg / 1.5 mL concentration for the Egyptian market. This formulation contains somatropin produced by recombinant DNA technology in bacteria, is functionally identical to human endogenous growth hormone, and is offered in a more concentrated form to reduce injection burden and minimize treatment interruptions; it is indicated for pediatric short stature (e.g., in Turner syndrome, small-for-gestational-age children, Prader–Willi syndrome) and adult GH deficiency, and is priced to broaden access under Egypt’s Vision 2030 public‑health initiative.

What Are Latest Mergers And Acquisitions In The Synthetic Hormones Market?

In November 2023, Aspen Pharmacare Holdings Limited, a South Africa-based pharmaceutical company, acquired Sandoz's Chinese business for $100 million. This acquisition includes Sandoz's China business, which includes products such as the synthetic hormone injectable Sandostatin. This strategic move allows Aspen to expand its footprint and capabilities in China's pharmaceutical market. Sandoz (China) Pharmaceutical Co., Ltd. is a China-based pharmaceutical company that provides a range of pharmaceutical products, including synthetic hormones.

What Defines the Synthetic Hormones Market?

The synthetic hormones market consists of sales of anabolic steroids, insulin, oral contraceptives, and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Synthetic Hormones Market Report 2026?

The synthetic hormones market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the synthetic hormones industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.